

# Maggie Chon U Cheang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/343737/maggie-chon-u-cheang-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68  
papers

16,561  
citations

39  
h-index

75  
g-index

75  
ext. papers

18,782  
ext. citations

8.6  
avg, IF

5.73  
L-index

#	Paper	IF	Citations
68	Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. <i>Journal of Proteomics</i> , <b>2021</b> , 241, 104236	3.9	4
67	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 847-859	10.1	2
66	Development and validation for research assessment of Oncotype DX <sup>®</sup> Breast Recurrence Score, EndoPredict <sup>®</sup> and Prosigna <sup>®</sup> . <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 15	7.8	6
65	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
64	Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 190, 295-305	4.4	1
63	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 15	7.8	8
62	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 17	7.8	54
61	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	3
60	Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 175, 149-163	4.4	3
59	Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 21	7.8	27
58	Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients. <i>Breast Cancer Research</i> , <b>2019</b> , 22, 2	8.3	6
57	Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7485-7496	12.9	7
56	Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. <i>Cancers</i> , <b>2019</b> , 11,	6.6	5
55	A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 204-212	6.1	14
54	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. <i>Acta Oncologica</i> , <b>2018</b> , 57, 38-43	3.2	15
53	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , <b>2018</b> , 24, 628-637	50.5	410
52	Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky005	4.6	5

51	Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. <i>Breast Cancer Research</i> , <b>2018</b> , 20, 103	8.3	7
50	Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 165, 355-364	4.4	18
49	Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	25
48	Association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1006-1006	2.2	
47	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. <i>Nature Medicine</i> , <b>2016</b> , 22, 1303-1313	50.5	127
46	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1287-1294	13.4	65
45	Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 39	8.3	17
44	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 542-9	2.2	242
43	Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2405-16	12.9	36
42	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. <i>Cancer Discovery</i> , <b>2015</b> , 5, 488-505	24.4	76
41	Defining breast cancer intrinsic subtypes by quantitative receptor expression. <i>Oncologist</i> , <b>2015</b> , 20, 474-82	9.7	102
40	B-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. <i>Npj Breast Cancer</i> , <b>2015</b> , 1,	7.8	22
39	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , <b>2015</b> , 13, 303	11.4	87
38	Concordance of intrinsic subtyping and risk of recurrence (ROR) scores between matched primary and metastatic tissue from Triple Negative Breast Cancer Trial (TNT).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1019-1019	2.2	1
37	Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. <i>Radiation Research</i> , <b>2014</b> , 181, 193-207	3.1	10
36	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 511-21	12.9	143
35	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 506-506	2.2	11
34	Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1031-1031	2.2	

33	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 203-9	2.2	376
32	Predicting drug responsiveness in human cancers using genetically engineered mice. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4889-99	12.9	51
31	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. <i>Oncologist</i> , <b>2013</b> , 18, 123-33	5.7	376
30	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 132, 1049-62	4.4	252
29	Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2402-12	12.9	117
28	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1008-1008	2.2	12
27	Assessment of Topoisomerase II $\beta$ status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 1453-60	5.8	55
26	Breast cancer subtypes and the risk of local and regional relapse. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1684-91	2.2	903
25	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5222-32	12.9	546
24	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. <i>PLoS Medicine</i> , <b>2010</b> , 7, e1000279	11.6	616
23	Metastatic behavior of breast cancer subtypes. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3271-7	2.2	1300
22	Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 119, 53-61	4.4	90
21	Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1168-76	2.2	411
20	Reply to R.S. Mehta et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3068-3069	2.2	1
19	Supervised risk predictor of breast cancer based on intrinsic subtypes. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1160-7	2.2	2866
18	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 736-50	9.7	1545
17	Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. <i>Clinical Breast Cancer</i> , <b>2008</b> , 8, 249-56	3	118
16	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1368-76	12.9	917

15	Gene expression profiling of breast cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2008</b> , 3, 67-97	34	56
14	Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6944-54	12.9	65
13	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 110, 417-26	4.4	82
12	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. <i>BMC Cancer</i> , <b>2007</b> , 7, 134	4.8	284
11	Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5637-44	2.2	159
10	Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. <i>Cancer Research</i> , <b>2006</b> , 66, 4872-9	10.1	129
9	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 2492-502	27.4	2683
8	Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3039-47	2.2	150
7	MDM2 protein expression is a negative prognostic marker in breast carcinoma. <i>Modern Pathology</i> , <b>2006</b> , 19, 69-74	9.8	55
6	Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2005</b> , 24, 147-52	3.2	53
5	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. <i>Oncogene</i> , <b>2005</b> , 24, 4281-92	9.2	225
4	NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. <i>Oncogene</i> , <b>2005</b> , 24, 7281-9	9.2	57
3	Nuclear beta-catenin in mesenchymal tumors. <i>Modern Pathology</i> , <b>2005</b> , 18, 68-74	9.8	232
2	TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. <i>Modern Pathology</i> , <b>2005</b> , 18, 1641-8	9.8	35
1	Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6143-51	12.9	175